ANTITUMOR COMBINATION INCLUDING AVE8062 AND SORAFENIB

• US 20120108641A1
• Filed: 11/03/2011
• Published: 05/03/2012
• Est. Priority Date: 05/07/2009
• Status: Abandoned Application

• Current Assignee: Sanofi
• Original Assignee: Sanofi
• Inventors: DEMERS, Brigitte, VRIGNAUD, Patricia
• Application Number:
  US13/288,236
• Publication Number:
  US 20120108641A1
• Time in Patent Office: Days
• US Class Current: 514/350
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Combinations comprising AVE8062 and sorafenib are provided which are effective in the treatment of cancers, more particularly of solid tumours.

Claims

1. A composition comprising AVE8062 of formula:

2. The composition of claim 1, comprising an effective amount of AVE8062 and an effective amount of sorafenib.

3. The composition of claim 1, wherein the AVE8062 is in hydrochloride form and/or the sorafenib is in tosylate form.

4. The composition of claim 1, wherein the AVE8062 and the sorafenib are in amounts that produce a synergistic effect in reducing tumor volume in a patient when said composition is administered to a patient.

5. A method of treating a patient with cancer, comprising administering to said patient an effective amount of AVE8062 of formula:

6. The method of claim 5, wherein the effective amount achieves a synergistic effect in reducing tumor volume in said patient.

7. The method of claim 5, wherein the method comprises at least one cycle in which the administration of the AVE8062, or pharmaceutically acceptable salt or base thereof, is followed by several administrations of the sorafenib, or pharmaceutically acceptable salt or base thereof.

8. The method of claim 7, wherein the first of said several administrations of sorafenib, or pharmaceutically acceptable salt or base thereof, is administered one to four hours after the administration of the AVE8062, or pharmaceutically acceptable salt or base thereof.

9. The method of claim 7, wherein the first of said several administrations of sorafenib, or pharmaceutically acceptable salt or base thereof, is administered at least 24 hours after the administration of the AVE8062, or pharmaceutically acceptable salt or base thereof.

10. The method of claim 7, wherein the method comprises multiple cycles and the interval between the cycles is between one and four weeks.

11. The method of claim 5, wherein the AVE8062, or pharmaceutically acceptable salt or base thereof, is administered parenterally and the sorafenib, or pharmaceutically acceptable salt or base thereof, is administered orally.

12. The method of claim 5, wherein the cancer is a solid tumor.

13. The method of claim 5, wherein the cancer is selected from the group consisting of sarcoma, lung cancer, ovarian cancer, kidney cancer and liver cancer.